Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib Combinations in FLT3+ AML/MDS
NCT02400281Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crenolanib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by AROG Pharmaceuticals, Inc.. Started Sep 2015; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02400281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400281.